Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects.

[1]  J. Seghatchian,et al.  Ebola virus convalescent blood products: Where we are now and where we may need to go , 2014, Transfusion and Apheresis Science.

[2]  V. Compernolle,et al.  Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction , 2014, Transfusion.

[3]  V. Compernolle,et al.  Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion , 2014, Vox sanguinis.

[4]  C. Navarrete,et al.  Determination of human neutrophil antigen‐1, ‐3, ‐4 and ‐5 allele frequencies in English Caucasoid blood donors using a multiplex fluorescent DNA‐based assay , 2013, Vox sanguinis.

[5]  C. Prowse.  Component pathogen inactivation: a critical review , 2013, Vox sanguinis.

[6]  R. Benjamin,et al.  Plasma components: properties, differences, and uses , 2012, Transfusion.

[7]  S. Ausset,et al.  Use of freeze-dried plasma in French intensive care unit in Afghanistan. , 2011, The Journal of trauma.

[8]  R. Goodrich,et al.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light , 2011, Transfusion Medicine and Hemotherapy.

[9]  Lily Lin,et al.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM , 2011, Transfusion Medicine and Hemotherapy.

[10]  W. Struff,et al.  Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction , 2011, Transfusion Medicine and Hemotherapy.

[11]  P. Hellstern,et al.  The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma , 2011, Transfusion Medicine and Hemotherapy.

[12]  R. Seitz,et al.  Pathogen inactivation – regulators aspects , 2010 .

[13]  J. Cazenave,et al.  An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment , 2010, Transfusion.

[14]  L. Corash,et al.  INTERCEPT plasma: comparability with conventional fresh‐frozen plasma based on coagulation function – an in vitro analysis , 2010, Vox sanguinis.

[15]  S. Kleinman,et al.  Emerging infectious disease agents and their potential threat to transfusion safety , 2009, Transfusion.

[16]  T. Hervig,et al.  Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers , 2008, Transfusion.

[17]  B. Châtelain,et al.  Coagulation function in fresh‐frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen , 2007, Transfusion.

[18]  J. George,et al.  A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura , 2006, Transfusion.

[19]  L. Sawyer,et al.  Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function , 2006, Transfusion.

[20]  P. Mintz,et al.  Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. , 2006, Blood.

[21]  C. Kessler,et al.  Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies , 2005, Transfusion.

[22]  R. Dodd,et al.  Emerging infectious threats to the blood supply. , 2004, Annual review of medicine.

[23]  V. Ciaravino,et al.  Preclinical safety profile of plasma prepared using the INTERCEPT Blood System , 2003, Vox sanguinis.

[24]  L. Corash,et al.  Pharmacokinetic study of FFP photochemically treated with amotosalen (S‐59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin , 2002, Transfusion.

[25]  S. Wollowitz.  Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. , 2001, Seminars in hematology.